← ANALYST RATINGS · TIPRANKS
Kodiak Sciences (KOD): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy1 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $121, the highest $145, the lowest $103. The average is +41.3% from the last price of $85.75.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $32.00 → $80.00+150.0% | Hold | −6.7% | Reiterated | 15.10.26on TipRanks 06:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $33.00 → $84.00+154.5% | Hold | −2.0% | Reiterated | 15.10.26on TipRanks 06:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $33.00 → $82.00+148.5% | Hold | −4.4% | Reiterated | 15.10.26on TipRanks 06:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $33.00 → $81.00+145.5% | Hold | −5.5% | Upgrade | 15.10.26on TipRanks 06:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $32.00 → $81.00+153.1% | Hold | −5.5% | Reiterated | 15.10.26on TipRanks 06:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $32.00 → $79.00+146.9% | Hold | −7.9% | Reiterated | 15.10.26on TipRanks 06:06 | — | |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $96.00 → $126+31.2% | Buy | +46.9% | Reiterated | 12.10.26on TipRanks 06:30 | −0.6%next day −7.7% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $112 | Buy | +30.6% | Reiterated | 05.10.26on TipRanks 09:55 | −1.4%next day −2.1% · 5 days +5.4% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $36.00 → $103+186.1% | Hold | +20.1% | Reiterated | 29.09.26on TipRanks 21:10 | +4.2%next day +3.7% · 5 days −5.8% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | — | Buy | — | Reiterated | 28.09.26on TipRanks Sep 29 08:26 | +178.7%next day +1.5% · 5 days +3.1% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $80.00 → $120+50.0% | Buy | +39.9% | Reiterated | 28.09.26on TipRanks Sep 29 06:20 | +178.7%next day +1.5% · 5 days +3.1% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Reiterated | 28.09.26on TipRanks 11:55 | +178.7%next day +1.5% · 5 days +3.1% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $85.00 → $145+70.6% | Buy | +69.1% | Reiterated | 28.09.26on TipRanks 11:45 | +178.7%next day +1.5% · 5 days +3.1% | ↗ |
| Daniil Gataulin★★★★★★★★★★#2392 · hits 39% · avg +14.9% | Chardan Capital | $61.00 | Buy | −28.9% | Upgrade | 11.05.26on TipRanks 08:10 | −3.1%next day −0.8% · 5 days −12.0% | ↗ |
| Gena Wang★★★★★★★★★★#4240 · hits 44% · avg +2.4% | Barclays | $17.00 | Hold | −80.2% | Reiterated | 17.11.25on TipRanks 04:55 | +2.6%next day −2.2% · 5 days +9.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Kodiak Sciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $115 at a price of $94.80 (+21.5%); now: $121 at $85.75 (+41.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 4 | 3 | 5 | 7 | 7 |
| Buy | 6 | 4 | 2 | 2 | 7 | 9 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 12.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.06 (from $-1.32 to $-0.89). Last quarter: $-1.05.
Best top-analyst consensus in the sector · Healthcare
About Kodiak Sciences
- CEO: Victor Perlroth
- Employees: 141
- 1200 Page Mill Road, Palo Alto, CA, 94304, US
- kodiak.com
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Data from the stock’s TipRanks forecast page, read 63 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗